Lexston Announces Federal Funding for Cannabis Transformation Project That Will Result in Zero THC Varieties

Lexston Announces Federal Funding for Cannabis Transformation Project That Will Result in Zero THC Varieties

Vancouver, British Columbia, January 19, 2022. Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE: LEXT) (OTCQB: LEXTF) is pleased to announce that the company’s wholly owned subsidiary, Egret Bioscience Ltd. (“Egret”) has recently received funding from the Canadian government for their project on Cannabis transformation to develop new breeding techniques using CRISPR-Cas9 technology. The project, entitled “Screening of Egret’s hemp genotypes for proof of concept tissue culture and transformation method validation“ was initiated by the National Research Council of Canada (NRC) in July 2021 through their Industrial Research Assistance Program (NRC-IRAP). The Government contribution to the research totals over CAD$55,000. The goal of this year-long project is to develop new high essential oil hemp genotypes by manipulating the Cannabis sativa L. genome with the CRISPR gene editing system at targets identified by Egret scientists. On September 30, 2021, the NRC provided a project report for the initial stages of transformation of Cannabis tissue cultures. The team reported successfully creating cannabis protoplasts (cannabis cell cultures without cell walls) from four of Egret’s flagship essential oil hemp varieties: Hempress, Autopilot, Abacus and Suver Haze. The team also successfully transformed the protoplast with a marker protein, Green Fluorescent Protein (GFP) to validate the methods developed thus far.

Successfully transfected hemp protoplasts expressing Green Fluorescent Protein.

“We are tremendously excited to see the progress made by NRC Scientists, lead by Dr. Pankaj Bhowmik on four of the five varieties of essential oil hemp that we recently imported from the United States. Our high CBD, high essential oil content germplasm will be transformed into zero THC versions to ensure their compliance with the Canadian Industrial Hemp Regulations and the specification of the international hemp markets which requires hemp flowers to test below 0.3% total THC”, stated Philippe Henry PhD, Chief Science Officer and Director of Lexston. Lexston intends to leverage the methods developed through this initial research for future technology transfers into other species of interest to the company’s psychedelic pipeline.

For more information and to subscribe to the Company’s mailing list, please visit https://lexston.ca/contact/ 

About Lexston Life Sciences Corp.

Lexston Life Sciences Corp. (“Lexston”) is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health and wellness.

On Behalf of the Board of Directors


Jagdip Bal
Chief Executive Officer
Telephone: (604) 928-8913

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

929 Mainland Street Vancouver, BC V6B 1S3

Phone: (604) 928-8913

Fax: (604) 628-0129

Email: admin@lexston.net

Website: www.lexston.ca

Forward-Looking Statements

This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of LEXT to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.

Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Save the toads

Lexston Announces a Memorandum of Understanding to Collabborate on Psychedelics Research and Development With Alvarius Research Inc.

Did you know that potent psychedelics like 5-MeO-DMT and bufotenin come from the venom of the Colorado River Toad? 

With growing demand to study these compounds and increased recreational use, wild populations of the toad are threatened in some areas.

Alvarius Research Inc. recently developed a toad conservation program to address this issue. The company is also collaborating with Egret Bioscience to develop synthetic “toad-free” versions of the compounds.

A 7-year-old toad in the program named Little Buddha

PDF of article